You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 6,632,433

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,632,433

Title:	Method for treating cervical dystonia with botulinum toxin type B
Abstract:	A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
Inventor(s):	Aoki; K. Roger (Laguna Hill, CA), Grayston; Michael W. (Irvine, CA), Carlson; Steven R. (Laguna Niguel, CA), Leon; Judith M. (Laguna Niguel, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	09/884,830
Patent Claims:	1. A method for treating cervical dystonia in a human patient, the method comprising the step of administering to a human patient at least 500 units of a botulinum toxin type B to treat cervical dystonia. 2. The method of claim 1, wherein the botulinum toxin type B is administered by intramuscular injection or by subcutaneous injection. 3. The method of claim 1, wherein the administration of the botulinum toxin type B results in an alleviation of a symptom of the cervical dystonia within 1 day to about 7 days. 4. The method of claim 1, wherein the patient is administered at least 1,000 units of the botulinum toxin type B. 5. A method for treating cervical dystonia in a human patient, the method comprising the step of administering to a human patient an effective amount of botulinum toxin type B to treat cervical dystonia, wherein the botulinum toxin type B is administered by intramuscular injection, the administration of the botulinum toxin type B results in an alleviation of a symptom of the cervical dystonia within 1 day to about 7 days and the patient is administered at least 500 units of the botulinum toxin type B. 6. A method for treating cervical dystonia, the method comprising the step of administering to a human patient at least 500 units of a botulinum toxin type B, thereby reducing the severity of an abnormal head position symptom of cervical dystonia. 7. The method of claim 6, wherein the botulinum toxin type B is administered by intramuscular injection or by subcutaneous injection. 8. The method of claim 6, wherein the administration of the botulinum toxin type B results in an alleviation of a symptom of the cervical dystonia within 1 day to about 7 days. 9. A method for treating cervical dystonia, the method comprising the step of administering to a human patient at least 500 units of a botulinum toxin type B, thereby reducing a neck pain symptom of cervical dystonia. 10. The method of claim 9, wherein the botulinum toxin type B is administered by intramuscular injection or by subcutaneous injection. 11. The method of claim 9, wherein the administration of the botulinum toxin type B results in an alleviation of a symptom of the cervical dystonia within 1 day to about 7 days.

Details for Patent 6,632,433

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000	⤷ Try a Trial	2013-12-28
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001	⤷ Try a Trial	2013-12-28
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014	⤷ Try a Trial	2013-12-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 6,632,433

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Australia	1516295	⤷ Try a Trial
Australia	688452	⤷ Try a Trial
Australia	7010598	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.